About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon Quarterly Results
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
     
 
Financials

Financial Results

 
 
 

Current Financial Year 2018-19

  FY 18-19 Q1 H1 9M FY
  Notice Ad Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release - -
  Press Release Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release - -
  Fact Sheet Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release - -
  Transcript of the Call Biocon_Q1FY18_CallTranscript Biocon_Q2FY18_Call_Transcript - -
  Newspaper Advertisement Biocon_Q1 FY18_Press Release Biocon_Q2 FY19_Press Release - -
  Results Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release - -
  Investor Presentation Investor Presentation Investor Presentation - -

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q2FY19

Particulars 

Q2FY19

Q2FY18

Growth

INCOME

Small Molecules

432

351

23%

Biologics

367

156

136%

Branded Formulations

164

176

(7)%

Research Services

419

335

25%

Inter-segment

(61)

(49)

25%

Revenue from Operations#

1321

969

36%

Other Income

54

50

7%

TOTAL REVENUE

1375

1019

35%

EBITDA

394

233

69%

PBT

451

132

243%

Net Profit

355

69

416%

Exceptional Income (net of Tax)

171

NIL

Net Profit (excluding exceptional item)

184

69

167%

R&D Expenses in P&L

77

54

43%

Gross R&D Spends

120

96

25%

EBITDA Margin

29%

23%

Core EBITDA Margin

33%

26%

Net Profit Margin

13%

7%

#includes Licensing Income

5

8

Year 2017-18 Financial Highlights

In Rs. Crore 
  FY 17-18 Q1 H1 9M FY
  Revenue 988 1019 1092 1237
  EBITDA 246 233 256 300
  Net Profit 81 69 92 130
  R&D Expenses in P&L 58 54 53 51
  Total R&D Spends 96 93 94 98
  EBITDA Margins 25% 23% 23% 24%
  Core EBITDA Margin 29% 27% 27% 26%
  Net Profit Margins 8% 7% 8% 11%
 
  * As per the new accounting standard: Ind-AS  
  FY16-17  FY15-16  FY15-16  FY14-15  FY13-14  FY12-13  FY11-12  FY10-11  FY09-10  FY08-09  FY07-08  FY06-07  FY05-06  FY04-05 

 
Quarterly Results
 FY17-18
 FY16-17
 FY15-16
 FY14-15
 FY13-14
 FY12-13
 FY11-12
 FY10-11
 FY09-10
 FY08-09
 FY07-08
 FY06-07
 FY05-06
 FY04-05
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved